Director Meredith Manning filed a Form 4 with the SEC on October 29, 2026, disclosing the acquisition of restricted stock units and stock options in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) dated October 28, 2026.

Key Highlights

  • RSU grant: Manning acquired 3,350 restricted stock units on October 28, 2026, at a price of $0, payable solely in common stock of the issuer.
  • Vesting schedule: 837 shares vest upon grant and 209 shares vest monthly over 12 months beginning November 1, 2026, subject to continued service.
  • Stock options: Manning also acquired 27,000 stock options on October 28, 2026, with an exercise price of $3.76 and an expiration date of October 28, 2036.
  • Option exercise window: The stock options become exercisable beginning October 28, 2027, according to the filing.
  • Post-transaction holdings: Following these transactions, Manning beneficially owns 3,350 RSUs and 27,000 stock options, both held directly.
  • Role: The filing identifies Manning as a Director of Unicycive Therapeutics, Inc.

Director Manning Receives RSU and Option Awards at Unicycive Therapeutics

According to the Form 4 filed on October 29, 2026, Meredith Manning, a director of Unicycive Therapeutics, Inc., reported two derivative security acquisitions with a transaction date of October 28, 2026. Both transactions carried a price of $0 to the reporting person at acquisition. The filing was made as an individual filing by one reporting person and does not indicate any amendment to a prior filing.

The restricted stock unit grant covers 3,350 units convertible into common stock at a conversion price of $0. The filing's explanation of responses states that 837 shares vest upon grant, with the remaining units vesting at a rate of 209 shares per month over 12 months starting November 1, 2026, contingent on Manning's continued service with the issuer. Following the reported transaction, Manning directly and beneficially owns 3,350 RSUs.

Separately, Manning acquired 27,000 stock options with an exercise price of $3.76 per share. The options cover an underlying 27,000 shares of common stock, become exercisable on October 28, 2027, and expire on October 28, 2036. The price of the derivative security at acquisition is reported as $0. Following this transaction, Manning directly and beneficially owns 27,000 stock options. No non-derivative securities were reported in Table I of the filing.

What Was Disclosed

The filing disclosed that Director Meredith Manning received a grant of 3,350 restricted stock units and 27,000 stock options in Unicycive Therapeutics, Inc. on October 28, 2026, with vesting conditions and an exercise price of $3.76 for the options.